undamentalytics Newsletter
Sign in

Vertex Pharmaceuticals balance sheet

At the end of fiscal 2025, Vertex Pharmaceuticals had total assets of $25.64bn, total liabilities of $6.98bn and shareholders' equity of $18.67bn. It held $5.08bn in cash against $0 of debt.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents0.40.20.50.50.60.60.71.21.72.73.16.06.810.510.44.65.16.1
Receivables0.00.00.20.10.10.10.20.20.30.40.60.91.11.41.61.62.12.1
Inventory——0.10.00.00.00.10.10.10.10.20.30.40.50.71.21.71.8
Total current assets1.31.11.31.61.61.51.41.82.63.84.88.19.613.214.19.611.212.5
Goodwill0.00.00.00.00.00.00.10.10.10.11.01.01.01.11.11.11.11.1
Total assets2.01.72.22.82.32.32.52.93.66.38.311.813.418.222.722.525.627.4
Accounts payable0.00.00.10.10.00.10.10.10.10.10.10.20.20.30.40.40.50.4
Deferred revenue (current)0.10.10.00.00.00.00.00.00.0—————————
Total current liabilities0.30.50.40.40.40.40.50.80.81.11.31.92.12.73.53.63.93.9
Short-term debt—————0.00.10.0——————————
Long-term debt————0.00.30.20.0——————————
Total debt0.10.10.10.00.00.00.00.3——0.00.00.00.00.00.00.00.0
Total liabilities0.91.21.21.51.01.21.41.61.51.82.23.13.34.25.16.17.07.2
Shareholders' equity1.10.50.81.01.41.10.91.22.04.46.18.710.113.917.616.418.720.2
Non-controlling interests and other (assets − liabilities − equity)——0.20.2——0.20.2——————————
Shares outstanding200m204m209m217m234m242m246m248m253m255m259m260m254m257m258m257m254m253m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BIIB vs VRTXREGN vs VRTXINCY vs VRTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vertex Pharmaceuticals.